Vortioxetine

Introduction Overview

Generic Name

Vortioxetine

Brand Name

Trintellix

Dosage Form

Tablets (5 mg, 10 mg, 20 mg)

Drug Class

Miscellaneous antidepressants

Pharmacokinetics

Absorption:
Vortioxetine is orally administered and is rapidly and almost completely absorbed. Peak plasma concentrations typically occur approximately 7-11 hours post-dose under fasting conditions. The bioavailability of vortioxetine is not significantly affected by food intake, allowing for flexible administration with or without meals. Its absorption characteristics lead to steady-state plasma levels following once-daily dosing, supporting its use as a daily antidepressant agent.

Distribution:
Vortioxetine demonstrates extensive tissue distribution with a volume of distribution reported to be approximately 2600 liters, which indicates extensive extravascular distribution. It is highly bound to plasma proteins (~98%), primarily albumin, which influences its pharmacokinetics and potential drug-drug interactions. This high protein binding suggests vortioxetine is largely contained within the vascular compartment but with significant distribution to peripheral tissues, including the central nervous system.

Metabolism:
The drug is extensively metabolized in the liver primarily via cytochrome P450 enzymes, predominantly CYP2D6, with contributions from CYP3A4/5, CYP2C9, CYP2C19, and CYP2C8. The major metabolic pathway involves oxidation and subsequent glucuronic acid conjugation, producing several inactive metabolites. Genetic polymorphisms in CYP2D6 can lead to variations in metabolism rates; poor metabolizers may have increased plasma concentrations requiring potential dose adjustments. Clinical studies have demonstrated that inhibitors or inducers of CYP2D6 significantly affect vortioxetine exposure.

Elimination:
Vortioxetine and its metabolites are eliminated primarily via hepatic metabolism, with <1% of unchanged drug excreted in urine or feces. The half-life ranges approximately from 57 to 66 hours, supporting once-daily dosing and allowing for gradual elimination. Elimination is slower in poor CYP2D6 metabolizers, extending the half-life and increasing systemic exposure. This elimination profile minimizes the risk of accumulation but necessitates caution in patients with impaired hepatic function.

Dosage Forms

Available Dosage Forms:
Trintellix is supplied as immediate-release tablets for oral administration.
The available tablet strengths include:
- 5 mg tablets
- 10 mg tablets
- 20 mg tablets
These tablets contain the active ingredient vortioxetine hydrobromide along with inactive ingredients such as mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, and film coating components including hypromellose, titanium dioxide, polyethylene glycol 400, iron oxide red (for 5 mg and 20 mg), and iron oxide yellow (for 10 mg).

Dosages for Adults and Adolescents:
The recommended initial dose for adults diagnosed with major depressive disorder is 10 mg orally once daily.
Maintenance dosing ranges from 5 mg to 20 mg once daily, adjusted depending on patient tolerance and therapeutic response.
If patients do not tolerate the higher doses, dose reduction to 5 mg once daily is appropriate.
The maximum recommended dose is 20 mg per day.
Patients should be screened for bipolar disorder, mania, or hypomania before initiating therapy to mitigate risk of mood destabilization.

Specific Patient Populations:
- Pediatric patients: Trintellix is not approved for use in individuals under 18 years old due to a lack of safety and efficacy data.
- Elderly patients: No dose adjustment is generally required; however, careful monitoring is advisable due to increased risk of hyponatremia.
- Hepatic impairment: No specific dosage adjustments recommended, but caution is advised in severe hepatic impairment due to hepatic metabolism involvement.
- Renal impairment: No significant alterations in pharmacokinetics observed; no dose adjustment generally required.

Clinical guidelines recommend initiating therapy at a lower dose for patients with a history of poor tolerance to antidepressants or heightened sensitivity to serotonergic drugs.

Mechanism Of Action

Vortioxetine, marketed as Trintellix, functions primarily as a serotonin modulator and stimulator with a multimodal mechanism of action.

Primarily, vortioxetine acts as a potent inhibitor of the serotonin transporter (SERT), preventing serotonin reuptake into presynaptic neurons. This inhibition increases serotonin availability in the synaptic cleft, enhancing serotonergic neurotransmission, which is a well-established mechanism supporting antidepressant efficacy.

In addition to SERT inhibition, vortioxetine interacts with several serotonin receptor subtypes with distinct agonistic and antagonistic activities. It is an agonist of the 5-HT1A receptor, which plays a crucial role in mood regulation, anxiety reduction, and neuroplasticity. It is also a partial agonist at the 5-HT1B receptor and an antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors. These interactions contribute to vortioxetine's unique pharmacological profile, potentially improving cognitive function and reducing side effects commonly associated with traditional SSRIs.

The antagonism at 5-HT3 receptors has been linked to reduced incidence of nausea and gastrointestinal side effects, as this receptor subtype mediates emetic signaling. Additionally, blockade of 5-HT7 receptors by vortioxetine may yield procognitive and antidepressant benefits by modulating circadian rhythms and circadian-dependent mood regulation.

Preclinical and clinical studies have demonstrated that vortioxetine enhances the release of several neurotransmitters, including serotonin, norepinephrine, dopamine, acetylcholine, and histamine, via indirect mechanisms, further contributing to its antidepressant and cognitive-enhancing effects. Research evidence supports that through these multimodal actions, vortioxetine not only addresses core depressive symptoms but also improves cognitive symptoms often resistant to conventional antidepressants.

Pharmacological Actions

Selective serotonin reuptake inhibition enhancing serotonergic neurotransmission.
Agonism at 5-HT1A receptors improving mood and anxiety symptoms.
Partial agonism at 5-HT1B receptors modulating synaptic serotonin release.
Antagonism at 5-HT3 receptors mitigating nausea and gastrointestinal side effects.
Antagonism at 5-HT1D receptors influencing neurotransmitter dynamics.
Antagonism at 5-HT7 receptors potentially enhancing cognitive function and regulating circadian rhythms.
Modulation of multiple neurotransmitter systems including norepinephrine, dopamine, acetylcholine, and histamine indirectly improving mood and cognition.
Neuroplasticity enhancement through serotonin receptor modulation.
Improvement in cognitive symptoms associated with major depressive disorder.
Reduction of anxiety symptoms secondary to serotonergic modulation.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Management of depressive symptoms including mood, sleep, appetite, and energy disturbances.
Improvement of cognitive dysfunction associated with depression such as impaired concentration and memory.
Adjunctive therapy for patients with MDD unresponsive to other antidepressants (off-label usage under physician discretion).
Use in patients with comorbid anxiety disorders due to anxiolytic effects from 5-HT1A receptor agonism.
Potential benefit in elderly patients with depression complicated by cognitive deficits.
Treatment option for patients intolerant to traditional SSRIs due to improved side effect profile.
Therapeutic option that may reduce suicidal ideation and behavior through mood stabilization.
Off-label use in addressing depressive symptoms in patients with comorbid chronic neurological conditions (clinical discretion required).

Side Or Adverse Effects

Nausea occurring in approximately 26% of patients, typically mild to moderate and transient.
Diarrhea reported in about 7% of patients during clinical trials.
Dry mouth experienced by roughly 7% of individuals taking Trintellix.
Dizziness documented in approximately 6% of users.
Constipation affecting about 5% of patients.
Vomiting experienced by 5% of patients.
Flatulence (gas) occurring in 3% of cases.
Pruritus (itchy skin) reported in 2% of patients.
Risk of serotonin syndrome, especially when used concomitantly with other serotonergic drugs.
Possible worsening of mood including anxiety, agitation, irritability, or suicidal ideation during initial treatment phases.
Allergic reactions such as hives and swelling requiring immediate medical attention.
Rare cases of hyponatremia, particularly in older adults, with symptoms including confusion and weakness.
Vision disturbances including eye pain and redness.
Increased risk of bleeding when combined with anticoagulants or NSAIDs.
Withdrawal symptoms upon abrupt discontinuation characterized by dizziness, irritability, and sensory disturbances.

Precautions

Screen patients for bipolar disorder, mania, and hypomania prior to initiating treatment to prevent mood destabilization.
Monitor for serotonin syndrome symptoms when used with other serotonergic agents.
Use cautiously in patients with a history of seizures or epilepsy due to potential lowering of seizure threshold.
Exercise caution in patients with bleeding disorders or those receiving anticoagulant therapy due to increased bleeding risk.
Advise patients about potential hyponatremia, especially elderly individuals or those on diuretics and monitor serum sodium as clinically indicated.
Inform patients about the risk of withdrawal symptoms and recommend gradual dose tapering under medical supervision.
Avoid abrupt discontinuation to reduce risk of discontinuation syndrome.
Use during late pregnancy may lead to neonatal complications; benefits and risks must be carefully weighed.
Advise patients to avoid activities requiring mental alertness until drug effects are known due to potential dizziness.
Carefully assess patients for history of drug or alcohol dependence.
Evaluate concomitant medications to prevent serious drug-drug interactions, especially with MAO inhibitors.
Regularly monitor mood changes and suicidal ideation particularly in young adults and during early therapy.
Caution in patients with glaucoma due to potential increase in intraocular pressure.
Encourage reporting of any allergic reactions immediately.
Use with caution when prescribing alongside NSAIDs, anticoagulants, or medications affecting serotonin metabolism.

Warnings

Do not use Trintellix within 14 days of taking monoamine oxidase (MAO) inhibitors due to risk of serotonin syndrome.
After discontinuation of Trintellix, wait at least 21 days before starting an MAO inhibitor to avoid serious interactions.
Increased risk of suicidal thoughts and behaviors in young adults when beginning antidepressant therapy.
Potential for serotonin syndrome either alone or in combination with other serotonergic drugs; symptoms include altered mental status, autonomic instability, and neuromuscular abnormalities.
Use during the last trimester of pregnancy may cause neonatal complications including withdrawal symptoms and pulmonary hypertension.
Do not administer to pediatric patients under 18 years old as safety and efficacy are not established.
Avoid sudden discontinuation to prevent withdrawal symptoms.
Monitor for abnormal bleeding, especially during concomitant use with anticoagulants and NSAIDs.
Potential for hyponatremia, especially in elderly patients; monitor and evaluate symptoms of low sodium.
Use caution in patients with a history of bipolar disorder to avoid precipitating mania or hypomania.
Patients should be aware of possible vision changes and seek prompt evaluation if they occur.
Impaired driving or operating machinery may occur; avoid such activities until effects are understood.
Serious allergic reactions can occur; immediate emergency care is necessary for signs such as facial swelling or hives.
Patients with history of seizures require cautious use and close monitoring.
Potential drug interaction risks necessitate review of all current medications before initiation.

Contraindication

Known hypersensitivity to vortioxetine or any of the tablet's inactive ingredients.
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs due to risk of serotonin syndrome.
Use of MAOIs within 21 days after stopping Trintellix is contraindicated.
Hypersensitivity reactions to prior vortioxetine exposures.
Children and adolescents under 18 years of age due to lack of safety and efficacy data.
Concurrent use with methylene blue injection and other potent MAO inhibitors.
History of serotonin syndrome or neuroleptic malignant syndrome with vortioxetine or serotonergic agents.
Use in patients with known narrow-angle glaucoma requiring caution; absolute contraindication if elevated intraocular pressure is uncontrolled.
Patients with severe hepatic impairment where data is lacking to support safe use.
Patients with severe uncontrolled seizures or epilepsy.

Drug Interactions

Increased risk of serotonin syndrome when used with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, St. John's Wort, and tryptophan.
Co-administration with MAO inhibitors contraindicated due to severe interactions causing serotonin syndrome.
Inhibitors and inducers of CYP2D6 (e.g., fluoxetine, paroxetine) can alter vortioxetine plasma levels impacting efficacy and safety.
Concurrent use with NSAIDs (aspirin, ibuprofen, naproxen, celecoxib, diclofenac, indomethacin, meloxicam) may increase bleeding risk.
Drugs that impair platelet aggregation, such as anticoagulants (warfarin, coumadin, Jantoven), can have additive bleeding effects when combined with vortioxetine.
Seizure threshold may be lowered when combined with anticonvulsants like carbamazepine and phenytoin.
Possible interaction with stimulant medications and opioids potentially exacerbating serotonin syndrome.
Interaction with diuretics may increase hyponatremia risk.
Herbal supplements, especially St. John's Wort, may increase serotonergic effects and risk of adverse events.
Caution with drugs metabolized by CYP enzymes involved in vortioxetine clearance to prevent altered drug exposure.
Concomitant use with certain migraine medications (triptans) heightens serotonin syndrome risk.
Co-administration with other antidepressants requires careful monitoring for additive CNS effects.
Potential pharmacodynamic interaction with psychotropic drugs affecting serotonin and mood.
Monitoring is recommended when combined with medicines that affect sodium levels or electrolyte balance.
Not all possible drug interactions are known; patients should inform healthcare providers of all medications and supplements they are taking.

Preparations Of The Drug

Immediate-release oral tablets of vortioxetine hydrobromide.
Dosage strengths include 5 mg, 10 mg, and 20 mg tablets.
Tablets contain inactive ingredients such as mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate.
The film coating includes hypromellose, titanium dioxide, polyethylene glycol 400, iron oxide red (for 5 mg and 20 mg tablets), and iron oxide yellow (for 10 mg tablets).
Packaged in blister packs or bottles depending on the manufacturer and dispensing pharmacy.
Supplied for oral administration with guidance for once-daily dosing.
Distributed by Takeda Pharmaceuticals America, Inc. and marketed by Lundbeck.
Not available in generic form as of current 2025 data.
Shelf storage recommendation at room temperature away from moisture and heat.
Availability restricted to prescription use only.
Patient information leaflets accompany the medication for education on administration and side effects.
Discontinued formulations or different brand names such as Brintellix available in other regions.
Coupons and patient assistance programs available to reduce out-of-pocket expenses.
Not formulated for pediatric use or other dosage forms such as liquids or injectables.